NasdaqGM - Nasdaq Real Time Price USD

Iovance Biotherapeutics, Inc. (IOVA)

Compare
9.37 -0.22 (-2.29%)
As of 2:45 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Frederick G. Vogt Esq., J.D., Ph.D. Interim CEO, President, General Counsel, Corporate Secretary & Director 1.43M -- 1974
Mr. Jean-Marc Bellemin M.B.A. CFO, Principal Accounting Officer & Treasurer 873.02k -- 1972
Dr. Igor P. Bilinsky Ph.D. Chief Operating Officer 873.02k -- 1973
Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer 967.97k -- 1967
Ms. Sara Pellegrino Vice President of Investor Relations & Public Relations -- -- --
Ms. Tracy Winton Executive Vice President of Human Resources -- -- --
Mr. Howard B. Johnson M.B.A. Chief Business Officer -- -- 1960
Dr. Raj K. Puri M.D., Ph.D. Executive VP of Regulatory Strategy & Translational Medicine -- -- --
Mr. Brian Shew M.B.A. Senior VP & Head of Digital and Information Technology -- -- --
Mr. Kevin Smyth Executive Vice President of Quality -- -- --

Iovance Biotherapeutics, Inc.

825 Industrial Road
Suite 400
San Carlos, CA 94070
United States
650 260 7120 https://www.iovance.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
557

Description

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Corporate Governance

Iovance Biotherapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 5. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 3; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

October 30, 2024 at 8:00 PM UTC - November 4, 2024 at 8:00 PM UTC

Iovance Biotherapeutics, Inc. Earnings Date

Recent Events

September 11, 2024 at 3:00 PM UTC

at HC Wainwright Global Investment Conference

September 10, 2024 at 6:35 PM UTC

at Robert W Baird Global Healthcare Conference

September 4, 2024 at 7:45 PM UTC

at Wells Fargo Healthcare Conference

August 9, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 8, 2024 at 8:30 PM UTC

Q2 2024 Earnings Call

August 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 28, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 11, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 3, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 24, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers